menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Cellenkos Announces to Present at ASH on CK0804 in Myelofibrosis

    PR NEWSWIRE

    Neurocrine Presents INGREZZA® Data at Psych Congress 2024

    PR NEWSWIRE

    Neurocrine Presents Data on INGREZZA® for Tardive Dyskinesia

    PR NEWSWIRE

    Neurocrine Presents Data On Chorea Improvements In Huntington`s

    PR NEWSWIRE

    Zydus gains final USFDA approval for Valbenazine Capsules

    EXPRESSPHARMA

    Neurocrine Launches INGREZZA® SPRINKLE For Easier Administration

    PR NEWSWIRE

    Neurocrine founder-CEO Gorman to retire in October

    REUTERS

    Neurocrine Biosciences` Huntington`s disease drug gets FDA approval

    PRESS RELEASE

    Neurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data

    PR NEWSWIRE

    Neurocrine Biosciences Announces U.S. FDA Accepts NDA for INGREZZA

    PR NEWSWIRE

    Neurocrine Presents Data at MDS International Congress of Parkinson`s Disease

    PR NEWSWIRE

    Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data

    PR NEWSWIRE

    Neurocrine Announces FDA Approval of INGREZZA Capsules for Huntington`s Disease

    PR NEWSWIRE

    Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data

    PR NEWSWIRE

    Neurocrine Announces Publication of Full KINECT™-HD Results of Valbenazine

    PR NEWSWIRE

    Lupin gets tentative USFDA approval to market generic valbenazine capsules

    ECONOMIC TIMES

    Neurocrine Bio Presents Data on In Vitro Dissolution Performance of INGREZZA

    PR NEWSWIRE

    Neurocrine Presents Data on Improvements Over Time with Use of INGREZZA

    PR NEWSWIRE

    Neurocrine Biosciences Announces U.S. FDA Accepts sNDA for Valbenazine

    PRNEWSWIRE

    Sandoz`s Generic Valbenazine Tosylate Receives Approval in the U.S.

    FDA

    Teva`s Generic Valbenazine Tosylate Receives Approval in the U.S.

    FDA

    Neurocrine Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine

    PRNEWSWIRE

    Zydus gets tentative USFDA approval for Valbenazine capsules

    HEALTH ET

    Zydus` Generic Valbenazine Tosylate Receives Approval in the U.S.

    FDA

    Neurocrine INGREZZA Data on Sustained Treatment Response at Psych Congress 2022

    PRNEWSWIRE

    Neurocrine Biosciences Presents New INGREZZA Data on Tardive Dyskinesia

    PRNEWSWIRE

    Neurocrine Announces Positive Phase 3 Data for KINECT-HD Study of Valbenazine

    PRNEWSWIRE

    Neurocrine to Present New INGREZZA and ONGENTYS Data at the MDS Congress

    PRNEWSWIRE

    Neurocrine Bioscience to Present Data for Tardive Dyskinesia &Parkinson Disease

    PRNEWSWIRE

    Teva’s weak pipeline hit by Tourette’s drug trial failure

    PMLIVE

    US backs Sanofi’s ‘fast-track’ coronavirus vaccine

    PMLIVE

    Neurocrine, Xenon ink R&D deal targeting rare form of epilepsy

    BIOPHARMA DIVE

    Neurocrine Biosciences Publishes Long-Term INGREZZA® (valbenazine)

    PR NEWSWIRE

    Neurocrine Biosciences to Present Data Analyses on INGREZZA® (valbenazine)

    PR NEWSWIRE

    Neurocrine flags a failure for Tourette syndrome study — shares sink

    ENDPTS

    Neurocrine Biosciences Smacked On Rising Expectations And Fraying Nerves

    SEEKING ALPHA

    As Teva`s Austedo gets more play, doctors are coming around

    FIERCE PHARMA

    After disappointing 2016, new drug approvals roared back to life in 2017

    FIERCE BIOTECH

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.